Systemic treatment of HER2‐positive metastatic breast cancer: A systematic review

We aimed to systematically review and summarize data from the available clinical trials that examined the treatment of HER2‐positive metastatic breast cancer.

[1]  H. Gómez,et al.  Abstract P4-12-26: A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801) , 2013 .

[2]  M. Pegram,et al.  Abstract P4-12-09: Results from a phase 2a study of trastuzumab emtansine, paclitaxel, and pertuzumab in patients with HER2-positive metastatic breast cancer , 2013 .

[3]  Sung-Bae Kim,et al.  A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. , 2013, European journal of cancer.

[4]  H. Gómez,et al.  Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Hudis,et al.  Phase III trial of non-pegylated liposomal doxorubicin (M) in combination with trastuzumab (T) and paclitaxel (P) in HER2+ metastatic breast cancer (MBC). , 2013 .

[6]  S. Swain,et al.  Exposure–efficacy relationship of trastuzumab emtansine (T-DM1) in EMILIA, a phase III study of T-DM1 versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC). , 2013 .

[7]  R. Greil,et al.  AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Amadori,et al.  Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. , 2013, The oncologist.

[9]  Farhat Yaqub.  T-DM1 for HER2-positive metastatic breast cancer. , 2013, The Lancet. Oncology.

[10]  E. Perez,et al.  Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Oh,et al.  The outcome of preoperative chemotherapy followed by surgery and upfront surgery for liver metastases from colorectal cancer. , 2013 .

[12]  H. Gómez,et al.  A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer , 2013, Breast Cancer Research and Treatment.

[13]  J. Baselga,et al.  Abstract S5-1: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC) , 2012 .

[14]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[15]  J. Baselga,et al.  Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Whelan,et al.  Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Ximing J. Yang,et al.  A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-overexpressing metastatic breast cancer (HER2+ MBC): A trial of the Eastern Cooperative Oncology Group (E1105). , 2012 .

[18]  J. Abraham.  Pertuzumab plus trastuzumab and docetaxel in HER2-positive metastatic breast cancer , 2012 .

[19]  M. Beckmann,et al.  Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. , 2012, Breast.

[20]  H. Kennecke,et al.  Gender differences in outcomes for early-stage colon cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[22]  R. Greil,et al.  S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC) , 2011 .

[23]  C. Geyer,et al.  S5-7: A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-272) vs Lapatinib Plus Capecitabine for 2nd/3rd-Line Treatment of HER2+ Locally Advanced or Metastatic Breast Cancer. , 2011 .

[24]  J. Baselga,et al.  Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  S. Loibl,et al.  Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. , 2011, European journal of cancer.

[26]  Bing-he Xu,et al.  5050 POSTER Lapatinib (L) in Combination With Paclitaxel (P) is an Effective and Tolerable Treatment in HER2-overexpressing Metastatic Breast Cancer (MBC) Patients , 2011 .

[27]  E. Perez,et al.  5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976) , 2011 .

[28]  T. Whelan,et al.  Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Desilvio,et al.  A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for HER2 overexpressing metastatic breast cancer (MBC). , 2011 .

[30]  W. M. Smit,et al.  Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. , 2011, Clinical breast cancer.

[31]  J. Bergh,et al.  Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Forbes,et al.  Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Casey,et al.  LAPATINIB (L) PLUS CAPECITABINE (C) IN HER2-POSITIVE METASTATIC BREAST CANCER (MBC): AN EXPLORATORY ANALYSIS OF OVERALL SURVIVAL (OS) BASED ON POSTSTUDY THERAPY , 2010 .

[34]  M. Casey,et al.  Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial , 2010, The oncologist.

[35]  R. Kreienberg,et al.  First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Baselga,et al.  Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Jassem,et al.  Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Makris,et al.  Safety of First-Line Letrozole Compared with Lapatinib Plus Letrozole in Patients with Postmenopausal Hormone Receptor Positive Metastatic Breast Cancer: EGF30008 Study. , 2009 .

[39]  J. Baselga,et al.  Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy. , 2009 .

[40]  S. Johnston,et al.  An Exploration of the Association of Quality-of-Life (QOL) Scores with Tumor Progression Status in First Line Hormone Receptor Positive, HER2+ Metastatic Breast Cancer (MBC) Patients Treated with Lapatinib Plus Letrozole or Letrozole Alone. , 2009 .

[41]  J. Mackey,et al.  Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Saeed Sadeghi,et al.  Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  S. Loibl,et al.  Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  S. Stein,et al.  Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment , 2009, Breast Cancer Research and Treatment.

[45]  S. Stein,et al.  Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer , 2008, British Journal of Cancer.

[46]  H. Gómez,et al.  Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  J. Klijn,et al.  Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study) , 2008 .

[48]  J. Baselga,et al.  A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy , 2008 .

[49]  H. Gómez,et al.  Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer , 2008 .

[50]  S. Loibl,et al.  Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05) , 2008 .

[51]  M. Casey,et al.  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses , 2008, Breast Cancer Research and Treatment.

[52]  E. Winer,et al.  Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study , 2007, Cancer.

[53]  D. Amadori,et al.  Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer , 2007, Breast Cancer Research and Treatment.

[54]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[55]  J. Forbes,et al.  BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  N. Robert,et al.  Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  David Grimes,et al.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  L. Mauriac,et al.  Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer , 2005 .

[59]  J. Baselga,et al.  Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2 , 2005 .

[60]  C. Hudis,et al.  Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. , 2004, Clinical breast cancer.

[61]  N. Robert,et al.  Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival , 2004 .

[62]  K. Mayne,et al.  672 Randomised phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancer , 2003 .

[63]  D. Osoba,et al.  Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  L. Harris,et al.  First-Line Herceptin® Monotherapy in Metastatic Breast Cancer , 2001, Oncology.

[66]  L. Norton,et al.  Metastatic breast cancer. Length and quality of life. , 1991, The New England journal of medicine.

[67]  David C Christiani,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[68]  L. Norton,et al.  International consensus guidelines for advanced breast cancer ( ABC 1 ) , 2012 .

[69]  J. Thigpen.  Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens , 2011 .

[70]  M. Buyse,et al.  Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  K. Eguchi,et al.  Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group , 2009, Breast Cancer Research and Treatment.

[72]  M. Peck.  Use of adjuvant herceptin in the treatment of HER2 positive breast cancer : what a healthcare provider needs to know , 2007 .

[73]  N. Robert,et al.  Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  D. Ribnikar,et al.  Metastatic breast cancer. , 2014, Current opinion in oncology.

[75]  W. Eiermann.  Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  T. Fleming,et al.  Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial , 1998 .

[77]  S. Franco,et al.  Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer , 2010, The oncologist.